Products - Endometrial cancers | Topic | NICE

Showing 12 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA963)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 April 2024
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 September 2023
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 June 2023
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA779)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 March 2022
Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
16 April 2025
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 May 2025
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
21 May 2025
Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 September 2025
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent TS ID 11808
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC